CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$48.92 USD
+0.63 (1.30%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $48.99 +0.07 (0.14%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$48.92 USD
+0.63 (1.30%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $48.99 +0.07 (0.14%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Zacks News
CRISPR Science and Stocks: Knowing Enough to Invest
by Kevin Cook
Can you learn enough about the science and the companies to invest with confidence?
Amgen Gets EU Nod to Add Survival Data on Blincyto's Label
by Zacks Equity Research
Amgen (AMGN) gets approval from the European Commission to add overall survival (OS) data from the TOWER study on the label of its leukemia drug, Blincyto.
Top Stock Picks for the Week of June 18, 2018
by Panel Of Zacks Experts
Tracey Ryniec and Kevin Cook look at a big energy explorer and one of the hot gene editing biotechs.
BioMarin Begins Pediatric Study on Achondroplasia Candidate
by Zacks Equity Research
BioMarin Pharmaceutical (BMRN) initiates phase II study on vosoritide for the treatment of achondroplasia in infants and children up to five years of age.
Idera Stock Down, Study on Dermatomyositis Candidate Fails
by Zacks Equity Research
Shares of Idera (IDRA) decline following the failure of a phase II study of its pipeline candidate, IMO-8400, on adult patients with dermatomyositis.
Has CRISPR THERAPTC (CRSP) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?
Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset
by Zacks Equity Research
Biogen (BIIB) signs a definitive option agreement to buy TMS-007, a phase II candidate, for the treatment of acute ischemic stroke (AIS) from private biotech TMS Co., Ltd.
Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex
by Zacks Equity Research
Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex
Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA
by Zacks Equity Research
FDA places clinical hold on a Vertex (VRTX) and CRISPR Therapeutics' IND application for CTX001 for the treatment of sickle cell disease.
Should You Buy the Dip in CRISPR Therapeutics?
by David Borun
A "Clinical Hold" from the FDA has the shares falling, but is it an opportunity to get in?
Is CRISPR THERAPTC (CRSP) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?
Is Genome Editing the Next Biotech Breakthrough?
by David Borun
CRISPR technology is promising to be the foundation the treatment of 1000s of diseases
Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?
CRISPR Therapeutics (CRSP) Jumps: Stock Rises 12.1%
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) was a big mover last session, as the company saw its shares more than 12% on the day amid huge volumes.
This Week In Tech Stocks
by Brian Bolan
A look at some tech stocks that are reporting earnings, coming out of a quiet period and one that is seeing its lockup expire today.